Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Daniel Lopez Della Vecchia"'
Autor:
Sofia Bruni, Florencia L Mauro, Cecilia J Proietti, Rosalia I Cordo-Russo, Martin A Rivas, Gloria Inurrigarro, Agustina Dupont, Dario Rocha, Elmer A Fernández, Ernesto Gil Deza, Daniel Lopez Della Vecchia, Sabrina Barchuk, Silvina Figurelli, David Lasso, Adrián D Friedrich, María C Santilli, María V Regge, Gabriel Lebersztein, Claudio Levit, Fabiana Anfuso, Teresa Castiglione, Patricia V Elizalde, Maria F Mercogliano, Roxana Schillaci
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background The success of HER2-positive (HER2+) breast cancer treatment with trastuzumab, an antibody that targets HER2, relies on immune response. We demonstrated that TNFα induces mucin 4 (MUC4) expression, which shields the trastuzumab epitope on
Externí odkaz:
https://doaj.org/article/260a8bffb8ab415c8e86847e61a3c8b1
Autor:
Roxana Schillaci, Sofia Bruni, Florencia Mauro, María F Mercogliano, Agustina Roldan-Deamicis, Cecilia J Proietti, Rosalía Cordo-Russo, Gloria Inurrigarro, Agustina Dupont, Carla Adami, Daniel Lopez Della Vecchia, Sabrina Barchuck, Silvina Figurelli, Ernesto Gil Deza, Sandra Ares, Felipe G Gercovich, Patricia V Elizalde
Publikováno v:
Cancer Research. 82:P5-13
Background HER2-positive (+) and triple negative breast cancer (TNBC) have the worst survival among BC. BC patients are treated with chemotherapy (CT) and/or radiotherapy (RT), and HER2+ BC patients also receive targeted therapies, such as trastuzuma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6ea5a7e8d26549966ddc698723e940da
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-32
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-32
Autor:
Nicolás Bellora, Franco Izzo, Rosalia Ines Cordo Russo, Pablo Guzmán, Juan Carlos Roa, Matías G. Pereyra, Mara De Martino, Mauro E. Cenciarini, Ezequiel Petrillo, Silvina Figurelli, Jose L. Daniotti, Daniel Lopez Della Vecchia, Osvaldo L. Podhajcer, Sabrina Barchuk, Lucía Santa María de la Parra, Patricia V. Elizalde, Violeta A. Chiauzzi, Cecilia J. Proietti, Leandro N. Guttlein, Roxana Schillaci, María F. Chervo, Agustina Dupont
Publikováno v:
Oncogene. 39:6245-6262
Triple negative breast cancer (TNBC) refers to tumors that do not express clinically significant levels of estrogen and progesterone receptors, and lack membrane overexpression or gene amplification of ErbB-2/HER2, a receptor tyrosine kinase. Transcr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e380a9b060f637fc53453e0dda07e75
https://doi.org/10.1038/s41388-020-01430-9
https://doi.org/10.1038/s41388-020-01430-9
Autor:
Patricia V Elizalde, Rosalia Cordo Russo, Santiago Madera, Sharon S Merin, María F Chervo, Esmaeil Ebrahimie, Luke Selth, Violeta A Chiauzzi, Agustina Dupont, Sabrina Barchuk, Silvina Figurelli, Daniel Lopez Della Vecchia, Pablo Guzmán, Juan C Roa, Claudio Levit, Gabriel Lebersztein, Fabiana Anfuso, Cecilia J Proietti, Roxana Schillaci, Theresa E Hickey, Wayne D Tilley
Publikováno v:
Journal of the Endocrine Society. 6:A878-A878
ErbB-2, a member of ErbB family of receptor tyrosine kinases, is a key oncogenic driver in breast cancer. Despite clinical efficiency of ErbB-2-targeted therapies (trastuzumab, TZ), resistance to drugs is a major issue in the clinic. While ErbB-2 is
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d4fed870b0bb20a1ac5ef36bb608e15
https://doi.org/10.1210/jendso/bvac150.1817
https://doi.org/10.1210/jendso/bvac150.1817
Autor:
Pablo Guzmán, Juan Carlos Roa, Silvina Figurelli, Agustina Roldán Deamicis, Rosalia Ines Cordo Russo, Leandro Venturutti, Mauro E. Cenciarini, Felipe G. Gercovich, Agustina Dupont, María F. Chervo, Violeta A. Chiauzzi, Santiago Madera, Sabrina Barchuk, Daniel Lopez Della Vecchia, Cecilia Jazmín Proietti Anastasi, Patricia V. Elizalde, Matías G. Pereyra, Roxana Schillaci, Sandra L. Ares, Ernesto Gil Deza
Publikováno v:
Journal of the Endocrine Society
Hormone receptor-positive (HR+, estrogen and/or progesterone receptor-positive) and HER2-negative breast cancer (BC) subtype is a biologically heterogeneous entity that comprises 70% of BCs. This subtype includes both luminal (Lum) A- and B-like subt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fd8efa62e66cc6c4af7c9a0885b65b4
http://europepmc.org/articles/PMC7208765
http://europepmc.org/articles/PMC7208765
Autor:
Cecilia J. Proietti, Sandra L. Ares, Ernesto Gil Deza, Pablo Guzmán, Juan Carlos Roa, Agustina Dupont, Agustina Roldán Deamicis, Roxana Schillaci, Rosalia Ines Cordo Russo, Sabrina Barchuk, Franco Izzo, Felipe G. Gercovich, Matías G. Pereyra, Leandro Venturutti, Fabiana Anfuso, Patricia V. Elizalde, Eduardo Cortese, Teresa Castiglioni, Violeta A. Chiauzzi, Mauro E. Cenciarini, Santiago Madera, Gabriel Lebersztein, Silvina Figurelli, Claudio Levit, María F. Chervo, Daniel Lopez Della Vecchia
Publikováno v:
Hormonescancer. 11(5-6)
The hormone receptor-positive (estrogen and/or progesterone receptor (PR)-positive) and HER2-negative breast cancer (BC) subtype is a biologically heterogeneous entity that includes luminal A-like (LumA-like) and luminal B-like (LumB-like) subtypes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb9fe7a71af0ab81b933a7eaec0593ad
https://pubmed.ncbi.nlm.nih.gov/32632815
https://pubmed.ncbi.nlm.nih.gov/32632815